Controversy and conflict in the treatment of acute decompensated heart failure: Nesiritide as evidence-based treatment

Pharmacotherapy

Volumn 27, Issue 5, 2007, Pages 619-625

  Munger, Mark A ^a,c   Ng, Tien M H ^b   Van Tassell, Benjamin W ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Acute decompensated heart failure; ADHF; Cardiology; Evidence based treatment; Nesiritide; Safety

Indexed keywords

GLYCERYL TRINITRATE; NESIRITIDE; NITROPRUSSIDE SODIUM; PLACEBO;

ACUTE HEART FAILURE; CLINICAL TRIAL; COMMUNITY CARE; CONSENSUS; DRUG APPROVAL; DRUG SAFETY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; REVIEW;

ACUTE DISEASE; EVIDENCE-BASED MEDICINE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PRACTICE GUIDELINES;

EID: 34247875998     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.5.619     Document Type: Review

References (41)

1. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111: 1487-91.
2. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized clinical trails. JAMA 2005;293:1900-5.
3. U.S. Food and Drug Administration. Cardiovascular and renal drugs advisory committee meeting transcript May 25, 2002 (3749t2.rtf). Available from http://www.fda.gov/ohrms/dockets /ac/01/briefing/3749b2.htm. Accessed July 15, 2006.
4. Karkowsky A. 3749b2_02_02-FDA-Medical Review.pdf, NDA 20-920. U.S. Food and Drug Administration, May 15, 2001. Available from http://www.fda.gov. cder/audiences/acspage/ cardiovascularmeetings1.htm. Accessed July 15, 2006.
5. Hauptman PJ, Schnitzler MA, Swindle J, Burroughs TE. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA 2006;296:1877-84.
6. Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline [online exclusive article]. J Card Fail 2006;12:e1-122. Available from http://www.online jcf.com/article/ PIIS1071916405013618/abstract.
7. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-41.
8. Forman DE, Butler J, Want Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-7.
9. Krumholtz HM, Chen TY, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients ≥ 65 years of age with heart failure. Am J Cardiol 2000;85: 1110-11.
10. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
11. Scios Inc. Natrecor (nesiritide) prescribing information. Fremont, CA; 2005.
12. Colucci WS, Elkayam U, Horton DP, et al, for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-53.
13. Mills RM, Lejemtel TH, Horton DP, et al, for the Natrecor Study Group. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 1999;34:155-62.
14. Burger AJ, Horton DP Lejemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-8.
15. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004;94:595-601.
16. Yancy CW. Treatment with B-type nattiuretic peptide for chronic decompensated heart failure: insights learned from the follow-up serial infusion of nesiritide (FUSION) trial. Heart Fail Rev 2004;9:209-16.
17. Hebeler RF Jr, Oz MC, on behalf of the NAPA Investigators. Effect of perioperative nesiritide administration on postoperative renal function and clinical outcomes in patients undergoing cardiothoracic surgery [abstract]. Circulation 2006;113:e807-8.
18. Mentzer RM, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol 2007;49:716-26.
19. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ, for the ADHERE Scientific Advisory Committee Study Group and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure; classification and regression free analysis. JAMA 2005;29:572-80.
20. Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006;12:10-38.
21. Jain P, Massie BM, Gattis WA, Klein L, Gheorghiade M. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am J Cardiol 2003;145:S3-17.
22. Peacock WF, Holland R, Gyarmathy R, et al. Observations and treatment of heart failure with nesiritide: results from the PROACTION trial. J Emerg Med 2005;29:243-52.
23. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting. Am J Cardiol 2004;94:595-601.
24. O'Connor CM, Gattis WA, Uretsky BF, et al, for the FIRST Investigators. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan international randomized survival trial (FIRST). Am Heart J 1999;13(1 pt 1):78-86.
25. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE trial [abstract]. Circulation 2004;110(suppl 3):515.
26. Duffe MS, Califf RM, Adams KFJ, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
27. Abraham WT. Nesiritide and mortality risk: individual and pooled analyses of randomized controlled clinical trials. Rev Cardiovasc Med 2005;6(spring). Available from http://www .medreviews.com.
28. Abraham WT, Adams KF, Fonarow CC, et al, for the ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (ADHERE). J Am Coll Cardiol 2005;46(1):57-64.
29. Arnold LM, Crouch MA, Carroll NV, Oinonen MJ. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Pharmacotherapy 2006;26: 1078-85.
30. Abraham WT, Lowes BDE, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
31. Abraham WT. Nesiritide does not increase 30-day or 6-month mortality risk [abstract]. Circulation 2005:112(suppl II):II-676.
32. Panel of cardiology experts provides recommendations to Scios regarding Natrecor [press release]. Fremont, CA: Scios Inc.; June 13, 2005. Available from http://www.sciosinc.com/ scios/press/2005 Accessed May 3, 2006.
33. Clarkson PB, Wheeldon NM, Macleod C, Coutie W, MacDonald TM. Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects. Clin Sci (Lond) 1995;88:159-64.
34. Sakata Y, Yamamoto K, Masuyama T. et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 2001;19:1905-12.
35. Tamaura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000;97:4239-44.
36. Noviasky JA, Kelberman M, Whalen KM, Guharoy R, Darko W. Science or fiction: use of nesiritide as a first-line agent? Pharmacotherapy 2003;23:1081-3.
37. Sackner-Bernstein J, Aaronson KD. Nesiritide-not verified. N Engl J Med 2005;353:1525-7.
38. Topel EJ. Nesiritide-not verified. N Engl J Med 2005;353: 113-16.
39. Cleland JG, Coletta AP, Freemantle N, Velavan P Tin L, Clark AL. Clinical trials update from the American College of Cardiology meeting; CARE-HF and the remission of heart failure, women's health study, TNT, COMPASS-HP, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Fail 2005;7: 931-6.
40. Elkayam U, Bitar F, Akhter MW, Khan S, Patrus S, Derakhshani M. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther 2004;9:227-41.
41. de Lissovoy G, Steir DM, Ciesla G, Munger M, Burger AJ. Economic implications of nesititide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am J Cardiol 2003;92:631-3.